Turnstone Biologics (TSBX) Competitors $0.34 -0.01 (-2.16%) As of 01:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TSBX vs. ATHE, MRNS, INKT, ALLK, GBIO, KALA, TPST, ALXO, BCAB, and DAREShould you be buying Turnstone Biologics stock or one of its competitors? The main competitors of Turnstone Biologics include Alterity Therapeutics (ATHE), Marinus Pharmaceuticals (MRNS), MiNK Therapeutics (INKT), Allakos (ALLK), Generation Bio (GBIO), KALA BIO (KALA), Tempest Therapeutics (TPST), ALX Oncology (ALXO), BioAtla (BCAB), and Daré Bioscience (DARE). These companies are all part of the "pharmaceutical products" industry. Turnstone Biologics vs. Alterity Therapeutics Marinus Pharmaceuticals MiNK Therapeutics Allakos Generation Bio KALA BIO Tempest Therapeutics ALX Oncology BioAtla Daré Bioscience Turnstone Biologics (NASDAQ:TSBX) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability. Is TSBX or ATHE more profitable? Alterity Therapeutics' return on equity of 0.00% beat Turnstone Biologics' return on equity.Company Net Margins Return on Equity Return on Assets Turnstone BiologicsN/A -105.99% -87.27% Alterity Therapeutics N/A N/A N/A Does the MarketBeat Community prefer TSBX or ATHE? Alterity Therapeutics received 1 more outperform votes than Turnstone Biologics when rated by MarketBeat users. Likewise, 62.50% of users gave Alterity Therapeutics an outperform vote while only 44.44% of users gave Turnstone Biologics an outperform vote. CompanyUnderperformOutperformTurnstone BiologicsOutperform Votes444.44% Underperform Votes555.56% Alterity TherapeuticsOutperform Votes562.50% Underperform Votes337.50% Which has better valuation & earnings, TSBX or ATHE? Alterity Therapeutics has lower revenue, but higher earnings than Turnstone Biologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTurnstone Biologics$19.31M0.42-$55.20M-$3.07-0.11Alterity TherapeuticsN/AN/A-$12.54MN/AN/A Does the media refer more to TSBX or ATHE? In the previous week, Alterity Therapeutics had 4 more articles in the media than Turnstone Biologics. MarketBeat recorded 5 mentions for Alterity Therapeutics and 1 mentions for Turnstone Biologics. Turnstone Biologics' average media sentiment score of 1.87 beat Alterity Therapeutics' score of 0.31 indicating that Turnstone Biologics is being referred to more favorably in the media. Company Overall Sentiment Turnstone Biologics Very Positive Alterity Therapeutics Neutral Which has more volatility and risk, TSBX or ATHE? Turnstone Biologics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Do analysts rate TSBX or ATHE? Turnstone Biologics currently has a consensus price target of $0.45, suggesting a potential upside of 29.50%. Alterity Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 251.80%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Alterity Therapeutics is more favorable than Turnstone Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Turnstone Biologics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders & institutionals have more ownership in TSBX or ATHE? 52.5% of Turnstone Biologics shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 32.1% of Turnstone Biologics shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryAlterity Therapeutics beats Turnstone Biologics on 10 of the 14 factors compared between the two stocks. Get Turnstone Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for TSBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSBX vs. The Competition Export to ExcelMetricTurnstone BiologicsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.04M$2.95B$5.53B$7.93BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-0.1130.0722.5118.54Price / Sales0.42494.82397.62103.30Price / CashN/A168.6838.1834.62Price / Book0.083.176.734.25Net Income-$55.20M-$72.35M$3.22B$248.18M7 Day Performance-0.71%2.14%1.38%1.03%1 Month Performance-8.50%5.67%2.79%2.70%1 Year Performance-86.69%-23.57%15.41%4.05% Turnstone Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSBXTurnstone Biologics3.2166 of 5 stars$0.34-2.2%$0.45+32.4%-86.6%$7.87M$19.31M-0.1082Positive NewsGap DownATHEAlterity Therapeutics1.9804 of 5 stars$3.44-1.1%$12.00+248.8%+55.0%$30.64MN/A0.0010Short Interest ↑News CoveragePositive NewsMRNSMarinus Pharmaceuticals1.9497 of 5 stars$0.55-0.2%$4.79+771.6%-62.6%$30.32M$30.99M-0.22110Upcoming EarningsINKTMiNK Therapeutics2.7682 of 5 stars$7.60+1.3%$37.50+393.4%-19.0%$30.14MN/A-1.9530Positive NewsGap UpALLKAllakos4.6078 of 5 stars$0.33+0.3%$2.00+511.6%-71.1%$29.55MN/A-0.16190Upcoming EarningsShort Interest ↓Positive NewsGBIOGeneration Bio3.6072 of 5 stars$0.43-0.6%$7.33+1,609.4%-84.9%$28.75M$19.89M-0.20150Positive NewsKALAKALA BIO3.5033 of 5 stars$4.62+29.3%$15.00+225.0%-46.5%$28.26M$3.89M-0.3530Positive NewsGap UpTPSTTempest Therapeutics2.0158 of 5 stars$7.64-2.5%$30.00+292.9%-85.4%$26.87MN/A-4.9920Upcoming EarningsALXOALX Oncology2.5341 of 5 stars$0.50-5.9%$4.14+729.7%-97.0%$26.65MN/A-0.1740Upcoming EarningsBCABBioAtla2.9153 of 5 stars$0.46+2.3%$6.00+1,218.7%-85.2%$26.51M$11M-0.2760Upcoming EarningsNews CoverageDAREDaré Bioscience2.2865 of 5 stars$2.94+1.6%$24.00+717.7%-26.0%$25.89M$9,784.00-4.9530Short Interest ↓ Related Companies and Tools Related Companies Alterity Therapeutics Competitors Marinus Pharmaceuticals Competitors MiNK Therapeutics Competitors Allakos Competitors Generation Bio Competitors KALA BIO Competitors Tempest Therapeutics Competitors ALX Oncology Competitors BioAtla Competitors Daré Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TSBX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turnstone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Turnstone Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
